Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular biologic delivery
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsMorgan V. Fedorchak, Steven R. Little, Joel S. Schuman
Life of this patent
Estimating the term…
Abstract
A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
Claims27
A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid composition comprising agent-loaded polymer microparticles included in a thermoresponsive hydrogel, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
A method for ocular delivery of an agent to a subject, comprising administering the agent at the lower fornix of an eye in the subject by topically delivering to an eye a liquid composition comprising agent-loaded polymer microparticles included in a thermoresponsive hydrogel, and permitting the liquid composition to form in situ a gelled, sustained release film structure retained on the lower fornix of the eye, wherein the agent is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
A method for sustained delivery of an agent to an ocular organ in a subject for treating an ocular condition in the subject, comprising topically delivering to the ocular surface a liquid composition comprising agent-loaded polymer microparticles included in a thermoresponsive hydrogel, wherein the ocular condition is an allergy, myopia progression, corneal abrasions, corneal ulcers, local immunosuppression after corneal transplant, herpetic simplex keratitus, intracellular diseases affecting the eye, extracellular diseases affecting the eye, contact lens-associated condition, post-operative infection prophylaxis, wound healing, or retinal degeneration due to trauma.
A method for ocular delivery of an agent to a subject for treating an ocular condition in the subject, comprising administering the agent at the lower fornix of an eye in the subject by topically delivering to an eye a liquid composition comprising agent-loaded polymer microparticles included in a thermoresponsive hydrogel, and permitting the liquid hydrogel to form in situ a gelled, sustained release film structure retained on the lower fornix of the eye, wherein the ocular condition is an allergy, myopia progression, corneal abrasions, corneal ulcers, local immunosuppression after corneal transplant, herpetic simplex keratitus, intracellular diseases affecting the eye, extracellular diseases affecting the eye, contact lens-associated condition, post-operative infection prophylaxis, wound healing, or retinal degeneration due to trauma.
A composition comprising agent-loaded polymer microparticles dispersed within a thermoresponsive hydrogel, wherein the agent is an agent for treating an ocular condition selected from an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum, and the composition is configured for sustained topical ocular release of the agent.
24-28. (canceled)
A drug depot positioned in the lower fornix of an eye of a subject, wherein the drug depot comprises a gelled hydrogel comprising drug-loaded polymer microparticles, wherein the drug is an antibody, a fusion protein, a chemokine, an interleukin, a growth factor, albumin, immunoglobulin, an interferon, a peptide, stem cell-conditioned media, plasma or serum.
30-34. (canceled)
Dependencies are inferred from the claim text.